Ocular von Hippel-Lindau Disease – clinical characteristics and future directions

References

• Maher ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28(7):443–447.
   PubMed Web of Science ®Google Scholar
• Rasmussen A, Alonso E, Ochoa A, et al. Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease. BMC Med Genet. 2010;11(1):1–9.
   PubMed Web of Science ®Google Scholar
• Neumann HP, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet (London, England). 1991;337(8749):1052–1054.
   PubMed Web of Science ®Google Scholar
• Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–2067.
   PubMed Web of Science ®Google Scholar
• Hippel E. Über eine sehr seltene Erkrankung der Netzhaut. Albrecht Von Graefes Archiv Für Ophthalmologie. 1904;59(1):83–106.
   Google Scholar
• Studien Ber Kleinbirncysten Bau AL. Pathogenese und Beziehungen zur Angiomatosis Retinae. Acta Pathol Microbiol Scand. 1926;3(suppl 1):1–28.
   Google Scholar
• Melmon KL, Rosen SW. Lindau’s disease. Review of the literature and study of a large kindred. Am J Med. 1964;36:595–617.
   PubMed Web of Science ®Google Scholar
• Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–1320.
   PubMed Web of Science ®Google Scholar
• Maher ER, Neumann HPH, Richard S. Von Hippel–Lindau disease: A clinical and scientific review. Eur J Hum Genet. 2011;19(6):617–623.
   PubMed Web of Science ®Google Scholar
• Maher ER. Von Hippel-Lindau disease. Curr Mol Med. 2004;4(8):833–842.
   PubMed Web of Science ®Google Scholar
• Decker J, Neuhaus C, Macdonald F, et al. Clinical utility gene card for: von Hippel-Lindau (VHL). Eur J Hum Genet. 2014;22:1–4.
   Web of Science ®Google Scholar
• Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57.
   PubMed Web of Science ®Google Scholar
• Eijk-Van Os PG, Schouten JP. Multiplex ligation-dependent probe amplification (MLPA®) for the detection of copy number variation in genomic sequences. Methods Mol Biol. 2011;688:97–126.
   PubMedGoogle Scholar
• Singh AD, Rundle PA, Rennie I. Retinal vascular tumors. Ophthalmol Clin North Am. 2005;18:167–176.
   PubMedGoogle Scholar
• Singh AD, Nouri M, Shields CL, et al. Treatment of retinal capillary hemangioma. Ophthalmology. 2002;109(10):1799–1806.
   PubMed Web of Science ®Google Scholar
• Singh AD, Ahmad NN, Shields CL, et al. Solitary retinal capillary hemangioma: lack of genetic evidence for von Hippel-Lindau disease. Ophthalmic Genet. 2002;23(1):21–27.
   PubMedGoogle Scholar
• Kreusel KM, Bechrakis NE, Neumann HP, et al. Solitary juxtapapillary capillary retinal angioma and von Hippel-Lindau disease. Can J Ophthalmol. 2007;42(2):251–255.
   PubMed Web of Science ®Google Scholar
• Nielsen SM, Rhodes L, Blanco I, et al. Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol. 2016;34(18):2172–2181.
   PubMed Web of Science ®Google Scholar
• Wong WT, Yeh S, Chan CC, et al. Retinal vascular proliferation as an ocular manifestation of von Hippel-Lindau disease. Arch Ophthalmol (Chicago, Ill 1960). 2008;126(5):637–643.
   PubMedGoogle Scholar
• Chang JH, Spraul CW, Lynn ML, et al. The two-stage mutation model in retinal hemangioblastoma. Ophthalmic Genet. 1998;19(3):123–130.
   PubMed Web of Science ®Google Scholar
• Wong WT, Agron E, Coleman HR, et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease. Ophthalmology. 2008;115(1):181–188.
   PubMed Web of Science ®Google Scholar
• Magee MA, Kroll AJ, Lou PL, et al. Retinal capillary hemangiomas and von Hippel-Lindau disease. Semin Ophthalmol. 2006;21(3):143–150.
   PubMedGoogle Scholar
• Shively SB, Beltaifa S, Gehrs B, et al. Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease. J Pathol. 2008;216(4):514–520.
   PubMed Web of Science ®Google Scholar
• Webster AR, Maher ER, Moore AT. CLinical characteristics of ocular angiomatosis in von hippel-lindau disease and correlation with germline mutation. Arch Ophthalmol (Chicago, Ill 1960). 1999;117(3):371–378.
   PubMedGoogle Scholar
• Toy BC, Agrón E, Nigam D, et al. Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease. Ophthalmology. 2012;119(12):2622–2630.
   PubMed Web of Science ®Google Scholar
• McCabe CM, Flynn HW Jr., Shields CL, et al. Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes. Ophthalmology. 2000;107(12):2240–2248.
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Barrett J, et al. Vasoproliferative tumors of the ocular fundus. Classification and clinical manifestations in 103 patients. Arch Ophthalmol (Chicago, Ill.: 1960). 1995;113(5):615–623.
   PubMedGoogle Scholar
• Shane TS, Berrocal AM, Hess DJ. Bilateral fluorescein angiographic findings in unilateral Coats’ disease. Ophthalmic Surg Lasers Imaging. 2011;42 Online:e15–e17.
   PubMedGoogle Scholar
• Sigler EJ, Randolph JC, Calzada JI, et al. Current management of Coats disease. Surv Ophthalmol. 2014;59(1):30–46.
   PubMed Web of Science ®Google Scholar
• Knecht PB, Bosch MM, Helbig H. Fibrotic racemose haemangioma of the retina. Klin Monbl Augenheilkd. 2008;225:495–496.
   PubMed Web of Science ®Google Scholar
• Heimann H, Damato B. Congenital vascular malformations of the retina and choroid. Eye (Lond). 2010;24(3):459–467.
   PubMed Web of Science ®Google Scholar
• Turell ME, Singh AD. Vascular tumors of the retina and choroid: diagnosis and treatment. Middle East Afr J Ophthalmol. 2010;17:191–200.
   PubMedGoogle Scholar
• Pitkänen L, Tommila P, Kaarniranta K, et al. Retinal arterial macroaneurysms. Acta Ophthalmol. 2014;92(2):101–104.
   PubMed Web of Science ®Google Scholar
• Say EAT, Shah SU, Ferenczy S, et al. Optical coherence tomography of retinal and choroidal tumors. J Ophthalmol. 2012;2012:8–9.
   PubMedGoogle Scholar
• Shields CL, Materin MA, Shields JA. Review of optical coherence tomography for intraocular tumors. Curr Opin Ophthalmol. 2005;16(3):141–154.
   PubMedGoogle Scholar
• Grigoropoulos VG, Nikolaidis P, Emfietzoglou I, et al. Evolution of a juxtapapillary von Hippel-Lindau tumour examined by optical coherence tomography. Clin Exp Optom. 2012;95(2):237–240.
   PubMed Web of Science ®Google Scholar
• Almeida A, Kaliki S, Shields CL. Autofluorescence of intraocular tumours. Curr Opin Ophthalmol. 2013;24(3):222–232.
   PubMed Web of Science ®Google Scholar
• Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12(6):417–423.
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–823.
   PubMed Web of Science ®Google Scholar
• Liang X, Shen D, Huang Y, et al. Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease. Ophthalmology. 2007;114(1):147–156.
   PubMed Web of Science ®Google Scholar
• Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 1999;284(5414):657–661.
   PubMed Web of Science ®Google Scholar
• Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2(7):423–427.
   PubMed Web of Science ®Google Scholar
• Chan CC, Collins AB, Chew EY. Molecular pathology of eyes with von Hippel-Lindau (VHL) disease: a review. Retina. 2007;27(1):1–7.
   PubMed Web of Science ®Google Scholar
• Wang Y, Abu-Asab MS, Shen D, et al. Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma. Graefes Arch Clin Exp Ophthalmol. 2014;252(8):1319–1327.
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996;93(20):10595–10599.
   PubMed Web of Science ®Google Scholar
• Rubio A, Meyers SP, Powers JM, et al. Gastrointestinal pathology-part 2Hemangioblastoma of the optic nerve. Hum Pathol. 1994;25(11):1249–1251.
   PubMed Web of Science ®Google Scholar
• Chan CC, Chew EY, Shen D, et al. Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis. 2005;11:697–704.
   PubMed Web of Science ®Google Scholar
• Vortmeyer AO, Yuan Q, Lee Y-S, et al. Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol. 2004;55(5):721–728.
   PubMed Web of Science ®Google Scholar
• Zhou M, Shen D, Head JE, et al. Ocular clusterin expression in von Hippel-Lindau disease. Mol Vis. 2007;13:2129–2136.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu R, Wang Y, et al. Effects of down-regulation of clusterin by small interference RNA on human acute myeloid leukemia cells. Int J Clin Exp Med. 2015;8(11):20925–20931.
   PubMed Web of Science ®Google Scholar
• Muhammad LA, Saad F. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target. Expert Rev Anticancer Ther. 2015;15(9):1049–1061.
   PubMed Web of Science ®Google Scholar
• Wang X, Luo L, Dong D, et al. Clusterin plays an important role in clear renal cell cancer metastasis. Urol Int. 2014;92(1):95–103.
   PubMed Web of Science ®Google Scholar
• Nakamura E, Abreu-e-Lima P, Awakura Y, et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol. 2006;168(2):574–584.
   PubMed Web of Science ®Google Scholar
• Wong WT, Agron E, Coleman HR, et al. Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol (Chicago, Ill 1960). 2007;125(2):239–245.
   PubMedGoogle Scholar
• Mettu P, Agron E, Samtani S, et al. Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. Invest Ophthalmol Vis Sci. 2010;51(9):4464–4470.
   PubMed Web of Science ®Google Scholar
• Singh AD, Shields CL, Shields JA. von Hippel-Lindau disease. Surv Ophthalmol. 2001;46(2):117–142.
   PubMed Web of Science ®Google Scholar
• Peyman GA, Raichand M, Zeimer RC. Ocular effects of various laser wavelengths. Surv Ophthalmol. 1984;28(5):391–404.
   PubMed Web of Science ®Google Scholar
• Annesley WH Jr., Leonard BC, Shields JA, et al. Fifteen year review of treated cases of retinal angiomatosis. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3 Pt 1):OP446–OP453.
   PubMedGoogle Scholar
• Schmidt D, Natt E, Neumann HP. Long-term results of laser treatment for retinal angiomatosis in von Hippel-Lindau disease. Eur J Med Res. 2000;5(2):47–58.
   PubMedGoogle Scholar
• Oosterhuis JA, Rubinstein K. Haemangioma at the optic disc. Ophthalmologica. 1972;164(5):362–374.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45(3):195–214.
   PubMed Web of Science ®Google Scholar
• TAP Study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol (Chicago, Ill 1960). 1999;117(10):1329–1345.
   Google Scholar
• Singh AD, Kaiser PK, Sears JE. Choroidal hemangioma. Ophthalmol Clin North Am. 2005;18(1):151–161, ix.
   PubMedGoogle Scholar
• Barbezetto IA, Smith RT. Vasoproliferative tumor of the retima treated with PDT. Retina. 2003;23(4):565–567.
   PubMed Web of Science ®Google Scholar
• Sachdeva R, Dadgostar H, Kaiser PK, et al. Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol. 2010;88(8):e334–e340.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, et al. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;109(7):1256–1266.
   PubMed Web of Science ®Google Scholar
• Cerman E, Çekiç O. Clinical use of photodynamic therapy in ocular tumors. Surv Ophthalmol. 2015;60(6):557–574.
   PubMed Web of Science ®Google Scholar
• Baba T, Kitahashi M, Kubota-Taniai M, et al. Subretinal hemorrhage after photodynamic therapy for juxtapapillary retinal capillary hemangioma. Case Rep Ophthalmol. 2011;2(1):134–139.
   PubMedGoogle Scholar
• Mashayekhi A, Shields CL, Shields JA. Transient increased exudation after photodynamic therapy of intraocular tumors. Middle East Afr J Ophthalmol. 2013;20(1):83–86.
   PubMedGoogle Scholar
• Tsai F-Y, Lau L-I, Chen S-J, et al. Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel-Lindau disease. J Chin Med Assoc. 2014;77(1):52–56.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu H, Zhang K, et al. Massive exudative retinal detachment following photodynamic therapy for retinal hemangioma in von Hippel-Lindau Syndrome. Photodiagnosis Photodyn Ther. 2014;11(2):250–253.
   PubMed Web of Science ®Google Scholar
• Goto S, Oshima Y, Tsujikawa M, et al. Massive exudative retinal detachment after photodynamic therapy for peripheral retinal capillary hemangioma. Retin Cases Brief Rep. 2013;7(1):86–88.
   PubMedGoogle Scholar
• Kim HM, Park KH, Woo SJ. Massive exudative retinal detachment following photodynamic therapy and intravitreal bevacizumab injection in retinal capillary hemangioma. Korean J Ophthalmol. 2015;29(2):143–145.
   PubMedGoogle Scholar
• Selver OB, Yaman A, Saatci AO. Temporary exudative retinal detachment following photodynamic therapy in a patient with retinal capillary hemangioblastoma. Middle East Afr J Ophthalmol. 2011;18(3):246–248.
   PubMedGoogle Scholar
• Wong YM, Jalil A, Mathews J, et al. Exudative retinal detachment following photodynamic therapy for retinal capillary hemangioma. Can J Ophthalmol. 2010;45(3):299–300.
   PubMed Web of Science ®Google Scholar
• Kreusel KM, Bornfeld N, Lommatzsch A, et al. Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology. 1998;105(8):1386–1392.
   PubMed Web of Science ®Google Scholar
• Raja D, Benz MS, Murray TG, et al. Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel-Lindau disease: visual and anatomic outcomes. Ophthalmology. 2004;111(1):150–153.
   PubMed Web of Science ®Google Scholar
• Seibel I, Cordini D, Hager A, et al. Long-term results after proton beam therapy for retinal papillary capillary hemangioma. Am J Ophthalmol. 2014;158(2):381–386.
   PubMed Web of Science ®Google Scholar
• Journée-de Korver JG, Oosterhuis JA, de Wolff-Rouendaal D, et al. Histopathological findings in human choroidal melanomas after transpupillary thermotherapy. Br J Ophthalmol. 1997;81(3):234–239.
   PubMed Web of Science ®Google Scholar
• Sharma T, Krishnan T, Gopal L, et al. Transpupillary thermotherapy for circumscribed choroidal hemangioma: clinical profile and treatment outcome. Ophthalmic Surg Lasers Imaging. 2011;42(5):360–368.
   PubMedGoogle Scholar
• Mashayekhi A, Shields CL, Rishi P, et al. Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control. Ophthalmology. 2015;122(3):600–609.
   PubMed Web of Science ®Google Scholar
• Shields CL, Santos MC, Diniz W, et al. Thermotherapy for retinoblastoma. Arch Ophthalmol (Chicago, Ill 1960). 1999;117(7):885–893.
   PubMedGoogle Scholar
• Mochizuki Y, Noda Y, Enaida H, et al. Retinal capillary hemangioma managed by transpupillary thermotherapy. Retina. 2004;24(6):981–984.
   PubMed Web of Science ®Google Scholar
• Parmar DN, Mireskandari K, McHugh D. Transpupillary thermotherapy for retinal capillary hemangioma in von Hippel-Lindau disease. Ophthalmic Surg Lasers. 2000;31(4):334–336.
   PubMedGoogle Scholar
• Chan CC, Vortmeyer AO, Chew EY, et al. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol (Chicago, Ill 1960). 1999;117(5):625–630.
   PubMedGoogle Scholar
• Los M, Aarsman CJ, Terpstra L, et al. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Ann Oncol. 1997;8(10):1015–1022.
   PubMed Web of Science ®Google Scholar
• Dahr SS, Cusick M, Rodriguez-Coleman H, et al. Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina. 2007;27(2):150–158.
   PubMed Web of Science ®Google Scholar
• Wong WT, Liang KJ, Hammel K, et al. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease. Ophthalmology. 2008;115(11):1957–1964.
   PubMed Web of Science ®Google Scholar
• Chelala E, Dirani A, Fadlallah A. Intravitreal anti-VEGF injection for the treatment of progressive juxtapapillary retinal capillary hemangioma: a case report and mini review of the literature. Clin Ophthalmol. 2013;7:2143–2146.
   PubMedGoogle Scholar
• Hrisomalos FN, Maturi RK, Pata V. Long-term use of intravitreal bevacizumab (avastin) for the treatment of von hippel-lindau associated retinal hemangioblastomas. Open Ophthalmol J. 2010;4:66–69.
   PubMedGoogle Scholar
• Agarwal A, Kumari N, Singh R. Intravitreal bevacizumab and feeder vessel laser treatment for a posteriorly located retinal capillary hemangioma. Int Ophthalmol. 2016. doi:10.1007/s10792-016-0183-x. [Epub ahead of print].
   Google Scholar
• Slim E, Antoun J, Kourie HR, et al. Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review. Can J Ophthalmol. 2014;49(5):450–457.
   PubMed Web of Science ®Google Scholar
• Martin LK, Bekaii-Saab T, Serna D, et al. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. Onkologie. 2013;36(11):657–660.
   PubMedGoogle Scholar
• Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology. 2002;109(9):1745–1751.
   PubMed Web of Science ®Google Scholar
• Girmens JF, Erginay A, Massin P, et al. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol. 2003;136(1):194–196.
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2(9):673–682.
   PubMed Web of Science ®Google Scholar
• Rini BI. Sunitinib. Expert Opin Pharmacother. 2007;8(14):2359–2369.
   PubMed Web of Science ®Google Scholar
• Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12(1):107–113.
   PubMed Web of Science ®Google Scholar
• Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease. Ann Oncol. 2011;22(12):2661–2666.
   PubMed Web of Science ®Google Scholar
• Drolet DW, Green LS, Gold L, et al. Fit for the eye: aptamers in ocular disorders. Nucleic Acid Ther. 2016;26:127–146.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Eliott D, Wells JA, et al. A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2016;123(1):78–85.
   PubMed Web of Science ®Google Scholar
• Park S, Chan C-C. Von Hippel-Lindau Disease (VHL): A need for a murine model with retinal hemangioblastoma. Histol Histopathol. 2012;27(8):975–984.
   PubMed Web of Science ®Google Scholar
• van Rooijen E, Voest EE, Logister I, et al. von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish. Dis Model Mech. 2010;3(5–6):343–353.
   PubMed Web of Science ®Google Scholar